Handelsavisen
prelaunch
Companies ›Healthcare ›FRE.AX
FR
FRE.AX — ASX Pharmaceuticals

Fre.Ax

A$0,04
Open in Charts → Attach watcher ⌖
— —
AUD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
11,1M AUD
P/E
—
EV / Rev
—
Div yield
0,00 %
Op margin
-973,5 %
ROE
-169,3 %
Net margin
-897,8 %
Debt / equity
0,00
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

FRE.AX operates in the Pharmaceuticals industry, focusing on the development and commercialization of pharmaceutical products.

Business. FRE.AX operates in the Pharmaceuticals industry, focusing on the development and commercialization of pharmaceutical products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
-169,3 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning FRE.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to FRE.AX. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    FRE.AX operates in the Pharmaceuticals industry, focusing on the development and commercialization of pharmaceutical products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    FRE.AX has a market price of 0.04 AUD and a market capitalization of 11,390,159.4 AUD, indicating a small-cap profile. The company's price-to-book ratio is 7.32, and its price-to-tangible-book ratio is also 7.32, suggesting a premium valuation relative to its book value. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating a conservative capital structure. The current ratio of 5.47 suggests strong short-term liquidity.

    In terms of profitability, FRE.AX reported a net income of -2,634,430 AUD and an operating income of -2,856,520 AUD, indicating significant losses. The return on equity is -1.6927, and the return on assets is -1.4414, both of which are negative, suggesting poor returns for shareholders and asset utilization.

    The company's revenue is concentrated in a single segment, as disclosed in its financials, with no geographic diversification provided in the available data. This lack of diversification could pose a concentration risk, particularly if the company's primary market experiences economic downturns or regulatory changes.

    FRE.AX has a negative growth trajectory, with a significant decline in operating cash flow of -1,779,200 AUD and a free cash flow of -2,708,790 AUD. The company's capital expenditure of -82,980 AUD indicates ongoing investment, but the negative cash flows suggest that the company is not generating sufficient cash to support its operations or growth initiatives.

    The risk assessment for FRE.AX indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The company's conservative capital structure, with no long-term debt, and its strong current ratio of 5.47 support the low liquidity risk assessment. The dilution risk is also low, as there are no signs of imminent share issuance or dilution pressures.

    Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company's financial snapshot and valuation metrics remain consistent with the latest available data, with no new developments reported in the filings or transcripts.

    Key takeaways
    • FRE.AX is a small-cap pharmaceutical company with a market capitalization of 11,390,159.4 AUD.
    • The company is currently unprofitable, with a net income of -2,634,430 AUD and an operating income of -2,856,520 AUD.
    • FRE.AX has a conservative capital structure with no long-term debt and a current ratio of 5.47.
    • The company's negative cash flows and low profitability indicate a challenging financial position.
    • The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    A$0,04
    Market cap
    A$11.4M
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    7.3x
    P / Tangible bookⓘ
    7.3x
    Tangible book
    A$1.6M
    Net cashⓘ
    —
    Current ratioⓘ
    5.5
    Debt / equityⓘ
    0.0
    ROAⓘ
    -1.4%
    ROEⓘ
    -1.7%
    Cash conversionⓘ
    68.0%
    CapEx / revenueⓘ
    -28.3%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-973,5 %Bottom quartile
    Net Margin-897,8 %Bottom quartile
    ROE-169,3 %Bottom quartile
    Capex / Rev-28,3 %Bottom quartile
    D/E0,00Above P75
    Cash Conv0,68Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Capex To Revenue
      capital_expenditure / revenue
    Source documents
    • FRE.AX Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    FRE.AXCanonical
    ASX · AUD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage